431 related articles for article (PubMed ID: 24333488)
21. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
[TBL] [Abstract][Full Text] [Related]
22. [Icodextrin in peritoneal dialysis therapy].
Grzegorzewska AE; Antczak-Jedrzejczak D
Przegl Lek; 1999; 56(12):812-6. PubMed ID: 10789195
[TBL] [Abstract][Full Text] [Related]
23. Evidence for Biocompatible Peritoneal Dialysis Solutions.
Nataatmadja M; Cho Y; Johnson DW
Contrib Nephrol; 2017; 189():91-101. PubMed ID: 27951555
[TBL] [Abstract][Full Text] [Related]
24. Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve?
Chung SH; Stenvinkel P; Bergström J; Lindholm B
Perit Dial Int; 2000; 20 Suppl 5():S57-67. PubMed ID: 11229614
[TBL] [Abstract][Full Text] [Related]
25. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
[TBL] [Abstract][Full Text] [Related]
26. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum?
Nessim SJ; Perl J; Bargman JM
Kidney Int; 2010 Jul; 78(1):23-8. PubMed ID: 20336052
[TBL] [Abstract][Full Text] [Related]
27. Studying the effects of new peritoneal dialysis solutions on the peritoneum.
Chan TM; Yung S
Perit Dial Int; 2007 Jun; 27 Suppl 2():S87-93. PubMed ID: 17556337
[TBL] [Abstract][Full Text] [Related]
28. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients.
Zhou Q; Bajo MA; Del Peso G; Yu X; Selgas R
Kidney Int; 2016 Sep; 90(3):515-24. PubMed ID: 27282936
[TBL] [Abstract][Full Text] [Related]
29. Severe peritoneal mononucleosis associated with icodextrin use in continuous ambulatory peritoneal dialysis.
Martín J; Sansone G; Cirugeda A; Sánchez-Tomero JA; Muñoz C; Selgas R
Adv Perit Dial; 2003; 19():191-4. PubMed ID: 14763060
[TBL] [Abstract][Full Text] [Related]
30. The new peritoneal dialysis solutions: friends only, or foes in part?
ter Wee PM; van Ittersum FJ
Nat Clin Pract Nephrol; 2007 Nov; 3(11):604-12. PubMed ID: 17957197
[TBL] [Abstract][Full Text] [Related]
31. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
[TBL] [Abstract][Full Text] [Related]
32. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
[TBL] [Abstract][Full Text] [Related]
33. [Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis].
Haag-Weber M
Wien Klin Wochenschr; 2005; 117 Suppl 6():89-97. PubMed ID: 16437339
[TBL] [Abstract][Full Text] [Related]
34. [Systemic and intraperitoneal inflammation in peritoneal dialysis patients].
Opatrná S
Vnitr Lek; 2016; 62 Suppl 6():58-61. PubMed ID: 28124933
[TBL] [Abstract][Full Text] [Related]
35. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.
Kawanishi K; Honda K; Tsukada M; Oda H; Nitta K
Perit Dial Int; 2013; 33(3):242-51. PubMed ID: 23123670
[TBL] [Abstract][Full Text] [Related]
36. "Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?
Misra PS; Nessim SJ; Perl J
Semin Dial; 2017 Mar; 30(2):164-173. PubMed ID: 28251697
[TBL] [Abstract][Full Text] [Related]
37. Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature.
Liakopoulos V; Roumeliotis S; Gorny X; Eleftheriadis T; Mertens PR
Oxid Med Cell Longev; 2017; 2017():3494867. PubMed ID: 29750088
[TBL] [Abstract][Full Text] [Related]
38. [Which future solutions for peritoneal dialysis?].
Bonomini M; Di Liberato L; Rago C; Lombardi T; Sirolli V; Arduini A
G Ital Nefrol; 2021 Oct; 38(5):. PubMed ID: 34713640
[TBL] [Abstract][Full Text] [Related]
39. Mediators of inflammation and fibrosis.
Lai KN; Tang SC; Leung JC
Perit Dial Int; 2007 Jun; 27 Suppl 2():S65-71. PubMed ID: 17556333
[TBL] [Abstract][Full Text] [Related]
40. Is icodextrin peritonitis a reaction to bacterial endotoxins?
Marani M; Manenti F; Di Luca M; Cecchini R; Martello M; Kulurianu K
Perit Dial Int; 2002; 22(6):736-7. PubMed ID: 12556083
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
